BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that its 2013 Registration Document, has been registered with the French Market Authorities (Autorité des Marchés Financiers) on April 7, 2014.

The Registration Document is available to the public free of charge upon request as per current legal regulations at BioAlliance Pharma’s headquarters – 49 Boulevard du Général Martial Valin, 75015 Paris – and may be consulted at the https://valeriooldsite.wpenginepowered.com website (under Investors).

The Annual Financial Report, the Report of the Chairman of the Board of Directors on corporate governance and on internal control and risk management procedures, as well as the Related Auditors’ Report with information on the fees paid to the statutory auditors in 2013, are included in the 2013 Registration Document.